-

Vetoquinol: 2024 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2024.

  • January 24, 2024: 2023 Annual revenues (after market)
  • March 20, 2024: 2023 Annual results (confcall after market)
  • April 29, 2024: 2024 First quarter revenues (after market)
  • May 28, 2024: Annual shareholders’ meeting
  • June 6, 2024: Dividend payment
  • September 12, 2024: 2024 First semester results (confcall after market)
  • October 30, 2024: 2024 Third quarter revenues (after market)

Next update: Annual Sales 2023, January 24th, 2024 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,497 people as of June 30th, 2023.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

More News From Vetoquinol

Vetoquinol: Availability of the 2025 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News: On 29 April 2026, Vetoquinol (Paris:VETO) filed its 2025 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). The 2025 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “...

Vetoquinol: Sales for 1st Quarter 2026

LURE, France--(BUSINESS WIRE)--Regulatory News: Vetoquinol (Paris:VETO): Sales for the first quarter of 2026 amounted to €125 million, down 4.3% on a reported basis, flat (-0.3%) at constant exchange rates and up 1.2% compared to the previous year at constant exchange rates and excluding the complementary product line simplification program. The impact of exchange rates was historically high during the first quarter, reaching -€5.2 million, primarily in the United States (-€2.9 million) and Ind...

Vetoquinol: 2025 Annual Results

LURE, France--(BUSINESS WIRE)--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, “In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on...
Back to Newsroom